A Rich Pipeline Expected to Drive Industry’s Growth

Episode Summary

Executive Summary: The episode discusses Evaluate Pharma’s upbeat World Preview outlook, with Antonio Loverlino arguing that prescription drug sales should keep growing through 2022, driven by innovation, higher FDA approvals, and orphan-drug strategies. He also highlights risks: tougher payer scrutiny, pricing pressure, and a looming biologic patent cliff that could reshape competition.

Main Topics: Overall pharma growth outlook: Evaluate Pharma forecasts continued prescription drug sales growth through 2022, supported by innovation and a more productive development engine. Rising FDA approvals and R&D productivity: The discussion frames recent approval volumes as evidence that pharma R&D is becoming more effective, especially as companies align trials with regulatory expectations and target niche populations. Orphan drugs and niche markets: Orphan and rare-disease therapies are portrayed as a major growth engine because they address unmet needs and can demonstrate incremental benefit more clearly. Oncology and immunotherapy: Oncology remains the leading therapeutic area, with immunotherapies and combination regimens expected to play a major role despite affordability and safety challenges. Company ranking shifts and pipeline diversity: Roche’s rise past Novartis reflects the importance of broader, sometimes unconventional pipeline assets beyond core oncology programs. Pricing pressure and payer scrutiny: While legislative reform seems unlikely, insurers and pharmacy benefit managers are increasingly restricting access and demanding cost-effectiveness, which may slow growth. Biotech patent cliff and future competition: A new biologic patent cliff may create a different competitive dynamic than the classic small-molecule patent cliff, affecting branded and biosimilar markets.

Key Arguments: Drug sales can keep growing because the pipeline is healthier and more innovation is reaching the market. Higher FDA approval counts suggest better R&D productivity and better alignment between trial design and regulatory expectations. Orphan drugs are attractive because they focus on small, unmet-need populations where benefit is easier to prove. Most future sales growth will come from a mix of new R&D projects and smaller, specialized companies rather than only the largest pharma firms. Oncology will remain dominant, but immunotherapies—especially in combination regimens—raise both medical promise and affordability concerns. Roche’s strength is no longer only oncology; unconventional assets in areas like multiple sclerosis and hemophilia are also driving value. The U.S. is unlikely to enact sweeping drug pricing reform, but payers are already tightening access and using exclusion lists more aggressively. A biologic patent cliff is emerging and could create a major shift in competitive behavior compared with prior generic-driven patent losses.

Data Points: Projected pharma industry growth: 2.3% - Forecast for industry growth through 2022 based on sales-type consensus. FDA approvals in 2016: 66 - New U.S. drug approvals cited as a record level. Previous approval record: 60 - FDA approvals in 2014, previously the high-water mark. Historical annual average FDA approvals: 27 - Long-term average referenced as the prior norm before the recent increase. Expected growth contribution from orphan drugs: About half of growth - Orphan drugs are described as accounting for roughly 50% of the projected sales growth. Top 20 pharma companies growth: Below 20% average growth - Indicates growth is expected to be uneven, with smaller players benefiting more. Antiviral growth pattern: Surge followed by normalization/decline - Category’s growth slowed after the hepatitis C treatment boom.

Pivotal Quotes: "We foresee the pharma industry basically continuing growing for 2.3% ... through 2022." — Antonio Loverlino: Describing Evaluate Pharma’s baseline growth forecast. "This is really a key component of any new strategy. It’s really finding those niche unmet needs." — Antonio Loverlino: Explaining why orphan drugs continue to be central to industry growth. "The biologic patent cliff, the second era of patent cliff." — Antonio Loverlino: Characterizing the next major competitive risk facing biotech and branded biologics.

Implications: The industry outlook remains positive, but future winners will likely be companies with differentiated pipelines and niche assets. Expect continued growth, but also more payer pressure, tougher pricing scrutiny, and new competition from biologic expirations.